Direct oral anticoagulants for ventricular thrombus resolution: pilot trials show reassuring efficacy and safety compared to warfarin.
作者信息
Andreotti Felicita, Burzotta Francesco
机构信息
Cardiovascular Science Department, Fondazione Policlinico Universitario Gemelli IRCCS, Rome, Italy.
CardioThoracic Department, Catholic University Medical School, Rome, Italy.
出版信息
EuroIntervention. 2025 Jan 6;21(1):20-21. doi: 10.4244/EIJ-E-24-00068.
Abstract
摘要
相似文献
1
Direct oral anticoagulants for ventricular thrombus resolution: pilot trials show reassuring efficacy and safety compared to warfarin.直接口服抗凝剂用于溶解心室血栓：初步试验显示，与华法林相比，其疗效和安全性令人放心。
EuroIntervention. 2025 Jan 6;21(1):20-21. doi: 10.4244/EIJ-E-24-00068.
2
Effect of direct oral anticoagulants versus vitamin K antagonists or warfarin in patients with left ventricular thrombus outcomes: A systematic review and meta-analysis.直接口服抗凝剂与维生素K拮抗剂或华法林对左心室血栓患者预后的影响：一项系统评价和荟萃分析。
Rev Port Cardiol. 2023 Jan;42(1):63-70. doi: 10.1016/j.repc.2021.11.013. Epub 2022 Nov 9.
3
Direct oral anticoagulants or warfarin in patients with left ventricular thrombus after ST-elevation myocardial infarction: a pilot trial and a prespecified meta-analysis of randomised trials.ST段抬高型心肌梗死后左心室血栓患者使用直接口服抗凝剂或华法林：一项试点试验及随机试验的预先设定的荟萃分析
EuroIntervention. 2025 Jan 6;21(1):82-92. doi: 10.4244/EIJ-D-24-00527.
4
Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.新型口服抗凝剂（达比加群、利伐沙班、阿哌沙班）与华法林治疗心房颤动患者的疗效和安全性的荟萃分析。
Am J Cardiol. 2012 Aug 1;110(3):453-60. doi: 10.1016/j.amjcard.2012.03.049. Epub 2012 Apr 24.
5
Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.直接口服抗凝剂与华法林在预防慢性肾脏病房颤患者中风和全身性栓塞事件方面的比较
Cochrane Database Syst Rev. 2017 Nov 6;11(11):CD011373. doi: 10.1002/14651858.CD011373.pub2.
6
Efficacy of direct oral anticoagulants on the resolution of left ventricular thrombus-A case series and literature review.直接口服抗凝剂对左心室血栓溶解的疗效——病例系列及文献综述
JRSM Cardiovasc Dis. 2019 Apr 8;8:2048004019839548. doi: 10.1177/2048004019839548. eCollection 2019 Jan-Dec.
7
Risk of gastrointestinal bleeding with direct oral anticoagulants: a systematic review and network meta-analysis.直接口服抗凝剂相关的胃肠道出血风险：系统评价和网络荟萃分析。
Lancet Gastroenterol Hepatol. 2017 Feb;2(2):85-93. doi: 10.1016/S2468-1253(16)30162-5. Epub 2016 Nov 16.
8
Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.初发性无诱因静脉血栓栓塞症患者初始口服抗凝治疗后复发性静脉血栓栓塞症的二级预防
Cochrane Database Syst Rev. 2017 Dec 15;12(12):CD011088. doi: 10.1002/14651858.CD011088.pub2.
9
Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation.在无抗凝治疗或预防指征的癌症患者中进行口服抗凝治疗。
Cochrane Database Syst Rev. 2017 Dec 29;12(12):CD006466. doi: 10.1002/14651858.CD006466.pub6.
10
Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.采用混合治疗比较的荟萃分析方法评估口服抗凝剂用于静脉血栓栓塞症的长期治疗。
Clin Ther. 2014 Oct 1;36(10):1454-64.e3. doi: 10.1016/j.clinthera.2014.06.033. Epub 2014 Aug 3.
引用本文的文献
1
Discordant Antithrombotic Effects of Apixaban in Fibrillating Left Atria vs Post-Myocardial Infarction Left Ventricular Aneurysm.阿哌沙班在颤动左心房与心肌梗死后左心室室壁瘤中的抗血栓作用不一致。
JACC Case Rep. 2025 Jun 18;30(15):104416. doi: 10.1016/j.jaccas.2025.104416.
本文引用的文献
1
2024 ESC Guidelines for the management of chronic coronary syndromes.2024年欧洲心脏病学会慢性冠状动脉综合征管理指南
Eur Heart J. 2024 Sep 29;45(36):3415-3537. doi: 10.1093/eurheartj/ehae177.
2
When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review.当直接口服抗凝剂不应作为标准治疗时：JACC 最新观点综述。
J Am Coll Cardiol. 2024 Jan 23;83(3):444-465. doi: 10.1016/j.jacc.2023.10.038.
3
2023 ESC Guidelines for the management of acute coronary syndromes.2023年欧洲心脏病学会急性冠状动脉综合征管理指南。
Eur Heart J. 2023 Oct 12;44(38):3720-3826. doi: 10.1093/eurheartj/ehad191.
4
[Managing patients with left ventricular thrombosis after acute myocardial infarction: current evidence, uncertainties, and future perspectives].[急性心肌梗死后左心室血栓患者的管理：当前证据、不确定性及未来展望]
G Ital Cardiol (Rome). 2023 Mar;24(3):196-205. doi: 10.1714/3980.39622.
5
Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients.颅内出血与直接口服抗凝剂加单一抗血小板药物或三联抗栓治疗的支架血栓形成：房颤和经皮冠状动脉介入治疗/急性冠状动脉综合征患者随机试验的荟萃分析。
Europace. 2020 Apr 1;22(4):538-546. doi: 10.1093/europace/euz345.
6
Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation.非维生素K拮抗剂口服抗凝药与心房颤动指南的实际应用：最佳实施的障碍与策略
Europace. 2015 Jul;17(7):1007-17. doi: 10.1093/europace/euv068.
7
Fibrinogen as a marker of inflammation: a clinical view.
Blood Coagul Fibrinolysis. 1999 Feb;10 Suppl 1:S3-4.
8
Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure.心力衰竭中止血异常与神经内分泌活动的关系。
Am Heart J. 1994 Mar;127(3):607-12. doi: 10.1016/0002-8703(94)90670-x.
9
Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 and von Willebrand factor in acute myocardial infarction.早期冠状动脉再灌注可减弱急性心肌梗死中纤溶酶原激活物抑制剂-1和血管性血友病因子的促凝反应。
J Am Coll Cardiol. 1990 Dec;16(7):1553-60. doi: 10.1016/0735-1097(90)90300-e.
Zotero 插件